This article is more than 5 years old. Information may no longer be current.

Orexigen acquires US rights to Contrave

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Orexigen Therapeutics has completed the acquisition from Takeda Pharmaceutical Company, announced in March, of the U.S. rights to the anti-obesity medication Contrave, according to a company press release.

Contrave (naltrexone/bupropion extended-release tablets) received FDA approval in fall 2014 for the treatment of obesity and promotion of weight-loss maintenance when used as supplement to diet and exercise for people with overweight or obesity and at least one weight-related comorbidity (including hypertension, type 2 diabetes or high cholesterol). The medication combines two drugs in an extended-release formulation: Naltrexone is indicated to treat alcohol and opioid dependence, and bupropion is indicated to treat depression and seasonal affective disorder and to aid in smoking cessation.

With this acquisition, Orexigen has relaunched the drug with its own sales organization and is looking to expand the use of Contrave and Mysimba, as the drug is known in Europe.

“We are in full execution mode with our team of dedicated and seasoned individuals focused on growing the U.S. Contrave business in order to help improve the health and lives of obese patients struggling to lose weight,” Orexigen CEO Michael Narachi, said in the release.